Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
proline-rich acidic protein
(
PRAP
) gene was found previously to be expressed in the epithelial cells of the mouse and rat gastrointestinal tracts, and pregnant mouse uterus. This article describes the isolation, distribution, and functional characterization of the human homologue.
PRAP
was abundantly expressed in the epithelial cells of the human liver, kidney, gastrointestinal tract, and cervix.
PRAP
expression was significantly down-regulated in
hepatocellular carcinoma
and right colon adenocarcinoma compared with the respective adjacent normal tissues. Treatment of the cells with butyrate, trichostatin A, and 5'-aza-2' deoxycytidine caused increases in
PRAP
gene expression of up to 30-fold, suggesting that the gene is suppressed through epigenetic mechanisms involving histone deacetylation and methylation. To determine the significance of
PRAP
expression in cancer cells, we cloned
PRAP
and its two major splice variants from human colon and liver, and overexpressed it in HeLa, HT29, and HepG2 cells.
PRAP
caused cell growth inhibition in the cancer cell lines in transient transfection assays, colony formation assays, and in the growth rates of stable clones. The data suggest that
PRAP
and its variants may play an important role in maintaining normal growth homeostasis in epithelial cells. The epigenetic suppression of
PRAP
expression in cancer may cause growth dysregulation, a hallmark of the carcinogenic process.
...
PMID:The proline-rich acidic protein is epigenetically regulated and inhibits growth of cancer cell lines. 1458 59